abstract |
The present invention relates to an effector moiety capable of inducing an intracellular effect when present inside a mammalian cell, the effector moiety comprising a payload conjugated with one or more saponins. The present invention also relates to an antibody-drug conjugate comprising an effector moiety according to the present invention, or to a ligand-drug conjugate comprising an effector moiety of the present invention comprising an effector moiety comprising a covalently linked saponin. The present invention relates to therapeutic combinations comprising (a) an effector moiety of the invention comprising one or more saponins, and optionally a pharmaceutically acceptable excipient; and (b) an antibody-drug conjugate or ligand-drug conjugate, and optionally a pharmaceutically acceptable excipient. The invention further relates to a pharmaceutical composition comprising an effector moiety of the invention or an antibody-drug conjugate of the invention or a ligand-drug conjugate of the invention, wherein at least one saponin covalently linked to an effector molecule, and optionally pharmaceutically acceptable excipients. The present invention also relates to an effector moiety of the present invention or an antibody-drug conjugate of the present invention or a therapeutic combination of the present invention or a ligand-drug conjugate of the present invention or a pharmaceutical composition of the present invention for use as a medicament. Finally, the present invention also relates to an effector moiety of the present invention or an antibody-drug conjugate of the present invention or a therapeutic combination of the present invention or a ligand-drug conjugate of the present invention for use in the treatment or prophylaxis of cancer or an autoimmune disease or The present invention relates to a pharmaceutical composition. |